InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Common Stock Issued

Cash raised by issuing new shares.

InflaRx N.V.NASDAQ: IFRX

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued outflow shrinks to €0

Q1 FY2026 common stock issued was €0, compared with €16.14M a year earlier. Trailing-twelve-month common stock issued was €16.2M. Over 3 fiscal years it compounded at +139.7% a year.

Context

  • Common stock issued amounted to 110276.5% of revenue in FY2025, up 109614.0 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly common stock issued holds near €0 or moves back toward the trailing-twelve-month quarterly average of €4.05M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0-100.0% QoQ
Last fiscal yearDec 2025
€32.35M+2845.1% YoY
LTMMar 2026
€16.2M-6.0% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+2845.1%——
3-year CAGR+139.7%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

EUR · from the cash flow

Latest · FY2025
32.35M EUR
Year-over-year change
+2845.1%
4-year CAGR
-16.1%

Common Stock Issued vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.0% is the 4th highest of 6, against a peer median of +5.6%.
  • Common stock issued amounts to 55236.8% of revenue for IFRX, versus a peer median of 2164.7%.
IFRX Competitors
Common Stock Issued for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$103.37M USD+5.6%-81.2%103.8%
IMAImageneBio IncLTM Mar 2026$62.59M USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$50.07M USD———
ATYRaTyr Pharma, Inc.LTM Mar 2026$47.69M USD-6.8%+129.8%25101.6%
STTKShattuck Labs, Inc.LTM Mar 2026$26.22M USD+2495.6%+538.3%2621.6%
IFRXInflaRx N.V.LTM Mar 2026€16.2M EUR-6.0%+139.7%55236.8%
CNTBConnect Biopharma Holdings LimitedFY2025$1.09M USD+381.5%+293.1%1707.8%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$131K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD-100.0%-46.9%—
Peer median (excluding IFRX) —+5.6%+129.8%2164.7%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(43.83M)
Depreciation & Amortization669.43K596.6K567.78K485.11K402.93K
Deferred Income Tax1.16M0000
Stock-Based Compensation4.33M6.04M3.41M4.07M0
Change in Working Capital1.54M(9.77M)1M(2.28M)4.66M
Accounts Receivables00002.12M
Inventory00(11.37M)4.47M6.63M
Accounts Payables316.11K(3.52M)00(5.76M)
Other Working Capital1.22M(6.25M)12.37M(6.75M)1.68M
Other Non-Cash Items(2M)(1.13M)(131.29K)(4.76M)4.84M
Operating Cash Flow(39.94M)(33.74M)(37.81M)(48.56M)(33.92M)
Capital Expenditures(37.78K)(162.39K)(81.1K)(46.87K)(111.13K)
Acquisitions (Net)37.78K(19.52M)000
Purchases of Investments(97.52M)(64.47M)(104.05M)(35.34M)(44.28M)
Sales of Investments71.6M84M86.44M87.75M47.5M
Other Investing Activities(37.78K)19.52M01(3)
Investing Cash Flow(25.95M)19.36M(17.7M)52.36M3.11M
Debt Repayment(360.64K)(364.43K)(373.98K)(388.11K)(357.58K)
Common Stock Issued65.14M2.35M56.48M1.1M32.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.2M)(47.74K)(3.12M)(323.73K)14.11K
Financing Cash Flow61.58M1.94M52.99M386.45K32M
Effect of Forex Changes4.59M2.46M(974.1K)1.41M(1.37M)
Net Change in Cash281.31K(9.98M)(3.5M)5.61M(179.66K)
Free Cash Flow(39.97M)(33.91M)(37.89M)(48.6M)(34.03M)

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.